The Biotech Growth Trust PLC (BIOG) has published its unaudited half-year results for the six months ended 30 September 2026, reporting a net asset value per share total return of 14.8% and a share price total return of 22.9%. The trust's NAV per share rose from 1,414.6p to 1,623.8p, while the share price advanced from 1,260.0p to 1,548.0p over the period. The share price return modestly exceeded the NASDAQ Biotechnology Index benchmark gain of 21.6%, though the NAV underperformed the benchmark, primarily due to weakness in small-cap biotechnology holdings during September 2026.
Key Points
- The Biotech Growth Trust PLC (BIOG) — a closed-end investment trust focused on global biotechnology equities
- NAV per share rose 14.8% to 1,623.8p; share price gained 22.9% to 1,548.0p in the six months to 30 September 2026
- The company bought back 1,114,074 shares at a cost of £15.7m; discount narrowed from 10.9% to 4.7%; gearing reduced to zero by period end
- Investors may be watching whether the portfolio's repositioning towards large-cap exposure stabilises relative performance against the NASDAQ Biotechnology Index benchmark
September Interest Rate Shock Drove NAV Underperformance Against NASDAQ Biotechnology Benchmark
The trust's NAV underperformance relative to the 21.6% benchmark gain was concentrated in September 2026, when the yield on 10-year US Treasury bonds rose from 4.75% to 5.28% — a two standard deviation move, according to the announcement. This sharp rise in rates triggered a broad-based sell-off in pre-revenue, small-cap biotechnology companies, which represent a significant overweight position in the portfolio. The portfolio manager reduced the trust's small-cap exposure by 12% during the period, reallocating some capital to large-cap holdings and cutting gearing from between 5–10% of NAV to zero by 30 September 2026 to manage volatility.
Forte Biosciences, UroGen Pharma and Kiniksa Pharmaceuticals Led Portfolio Contributors
The top five contributors to performance were Forte Biosciences, UroGen Pharma, Kiniksa Pharmaceuticals, Vogenx, and Revolution Medicines. Forte Biosciences, developing a first-in-class anti-CD122 antibody for coeliac disease, was acquired by argenx for approximately $2.2 billion in August 2026 following positive clinical data for its lead asset FB102. UroGen Pharma benefited from strong commercial uptake of bladder cancer drug ZUSDURI and a new US patent extending protection through July 2044. Kiniksa delivered repeated quarterly revenue beats for Arcalyst in recurrent pericarditis alongside positive Phase 2 lifecycle data for follow-on candidate KPL-387. Five portfolio companies in total agreed to be acquired during the period.
£15.7m Share Buyback Programme Narrows Discount and Contributes 0.5% to NAV Return
The trust repurchased 1,114,074 shares during the period at an average discount of 9.0% to NAV, at a total cost of £15.7m, representing 5.6% of shares in issue at the start of the period. The buyback programme contributed 0.5% to the NAV return — equivalent to approximately 40% of the company's annual ongoing charges, the announcement states. The discount narrowed from 10.9% to 4.7% over the six months. At the time of the announcement, 18,815,240 shares remained in issue, and a further 617,327 shares had been repurchased since the period end, with the discount standing at 5.9%.
Board Confirms Geoff Hsu to Retire as Director at 2027 AGM While Continuing as Lead Portfolio Manager
Following a significant shareholder vote against his re-election at the July 2026 AGM, lead portfolio manager Geoff Hsu will retire from the board at the conclusion of the 2027 AGM. The announcement states this decision followed consultation with shareholders and forms part of the board's succession planning. Hsu has served as a director since 2018 and will continue in his role as lead portfolio manager, with no change to the management of the portfolio. Ongoing charges remain unchanged at 1.2%, and no performance fee provision is currently included within the company's NAV.




Please wait processing your request...